(Q38103647)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Has the time come for metronomics in low-income and middle-income countries? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Eddy Pasquier

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Nicolas André

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Shripad Banavali

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

e239-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Integrating cancer control into global health

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Facing a "slow-motion disaster"--the UN meeting on noncommunicable diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

The World Cancer Declaration: from resolution to action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Role of American Society of Clinical Oncology in low- and middle-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Moving cancer up the global health agenda

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Cancer mortality in India: a nationally representative survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Delivering affordable cancer care in high-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Projections of the cost of cancer care in the United States: 2010-2020.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Can we treat cancer for a dollar a day? Guidelines for low-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Can targeted therapy be successful without metronomic scheduling?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Metronomic chemotherapy: new rationale for new directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Drug repositioning: identifying and developing new uses for existing drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Biology of Cox-2: an application in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Statins and cancer: current and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Metformin: a rising star to fight the epithelial mesenchymal transition in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Targeted therapies: Using β-blockers to inhibit breast cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Global child health priorities: what role for paediatric oncologists?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Patient adherence and persistence with oral anticancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Business Models, Business Strategy and Innovation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Building Social Business Models: Lessons from the Grameen Experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Disruptive innovation in health care delivery: a framework for business-model innovation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Specialty care systems: a pioneering vision for global health

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

The efficacy and toxicity of SIOP preoperative chemotherapy in Malawian children with a Wilms tumour

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

Daring to practice low-cost medicine in a high-tech era

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970056-1

7 January 2021

10.1016/S1470-2045(13)70056-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23639324%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference